Tolerx Achieves Milestone With Completion Of Phase Ib Clinical Study Of TRX1 In Cutaneous Lupus Erythematosus
Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for the treatment of immune-mediated diseases, announced the successful completion of a Phase Ib clinical study of TRX1, a novel humanized anti-CD4 monoclonal antibody (MAb), in subjects with refractory cutaneous lupus erythematosus (CLE). The Phase Ib study was designed to assess the safety, tolerability, and pharmacokinetics of TRX1. Tolerx has received a milestone payment from Genentech, Inc. in conjunction with the completion of this study.
To read more, click here.
Profound Immune System Discovery Opens Door to Halting Destruction of Lupus
A researcher funded by the Lupus Research Institute (LRI) has discovered an entirely new and powerful molecular switch that controls the inflammatory response of the immune system. The major finding, reported in the December 14th issue of the journal Cell, means that new methods can now be pursued to shut down uncontrolled inflammation, restore immune system regulation, and treat chronic autoimmune disorders such as lupus.
To read more, click here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment